Company Description
Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
The company develops a nano-technology-based sublingual drug delivery system designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients, supplements, and nutraceuticals to increase bioavailability, improve speed of onset, and reduce side effects.
Its lead prescription product candidate, Sublingual High Dose Aspirin, targets pain management and anti-inflammatory applications.
The company also develops Alprazolam in a sublingual formulation for anxiety treatment and offers Buzz Bomb Caffeine, a sublingually administered caffeine pre-workout consumer supplement.
Additionally, it develops sublingual formulations of Melatonin for sleep aid, Sublingual ED for erectile dysfunction, testosterone products, and vitamins D, E, and K.
The company targets therapeutic applications including heart attack and stroke, anxiety, antiplatelet conditions, nausea, pain management, and inflammation.
The company also designs and manufactures engineered control systems that integrate mechanical engineering, electronics, and computer science for body, chassis, powertrain, electrical, and interior vehicle applications.
It offers HMI and actuation systems, safety systems, shift systems, pedal systems, park systems, mechanical control cables, and mechatronic systems.
Aspire-Lakewood Holdings, Inc. was formerly known as Aspire Biopharma Holdings, Inc. and changed its name to Aspire-Lakewood Holdings, Inc. in September 2026.
Aspire-Lakewood Holdings, Inc. was incorporated in 2021 and is based in Estero, Florida.
| Country | United States |
| Founded | 2021 |
| Industry | Auto Parts |
| Sector | Consumer Discretionary |
| CEO | Kraig Higginson |
Contact Details
Address: 23150 Fashion Drive Estero, Florida 33928 United States | |
| Phone | (415) 592-7399 |
| Website | aspirelakewoodholdings.com |
Stock Details
| Ticker Symbol | ASBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001847345 |
| CUSIP Number | 738920305 |
| ISIN Number | US7389203057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kraig T. Higginson | Interim Chief Executive Officer, President and Executive Chairman of the Board |
| Ernest J. Scheidemann Jr. | Chief Financial Officer |
| Stephen E. Quesenberry | General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2026 | 8-K | Current Report |
| Sep 8, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | SCHEDULE 13G | Filing |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 6, 2026 | SCHEDULE 13G/A | Filing |
| Jul 20, 2026 | 8-K | Current Report |
| Jul 2, 2026 | SCHEDULE 13G | Filing |